Streptococcus intermedius as a leading agent of brain abscess: retrospective analysis of a UK cohort

7 1 Institute of Translational Medicine, University of Liverpool, Ashton St, Liverpool, L69 3GE 8 2 Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS 9 Foundation Trust, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK 10 3 Department of Neuroradiology, Oxford University Hospitals NHS Foundation Trust, John 11 Radcliffe Hospital, Headington, Oxford OX3 9DU, UK 12 4 Department of Neurosurgery, Oxford University Hospitals NHS Foundation Trust, John 13 Radcliffe Hospital, Headington, Oxford OX3 9DU, UK 14 5 Nuffield Department of Medicine, University of Oxford, Medawar Building for Pathogen 15 Research, South Parks Road, Oxford OX1 3SY, UK 16 6 NIHR Oxford British Research Council (BRC), John Radcliffe Hospital, Headington, Oxford 17 OX3 9DU, UK 18

1 0 1 data from a large UK teaching hospital to examine the epidemiological and microbiological 1 0 2 trends of bacterial brain abscesses. We specifically undertook to address: i) Any evidence any host factors that are associated with specific outcomes, in order to identify high risk 1 0 7 cases, with implications for prognosis, monitoring and interventions. We collected data retrospectively from the electronic patient records of Oxford University individual records to remove paediatric cases, erroneously coded cases and those with non-1 1 7 bacterial causes (e.g. Toxoplasma gondii), and then reviewed electronic notes and results, 1 1 8 extracting the relevant data. The study was undertaken as a registered audit to determine 1 1 9 the quality of management of brain abscesses. Approval for this was given internally via the 1 2 0 OUH audit management team and we collected and stored data in accordance with relevant 1 2 1 governance standards. All data were anonymised prior to analysis. We audited each case for adherence to local antimicrobial guidelines, which are accessible 1 2 4 to clinical staff via intranet and the smartphone app 'Microguide'. For bacterial brain 1 2 5 abscesses, the antimicrobial advice is as follows: 1 2 6 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020. ; https://doi. org/10.1101org/10. /2020 • Urgent biopsy with collection of specimens for culture is recommended in most 1 2 7 cases; 1 2 8 • Empiric choice of antimicrobial therapy is ceftriaxone (2g iv bd) and metronidazole 1 2 9 (400mg tds po); 1 3 0 • Substitute the cephalosporin with ciprofloxacin in patients with a history of beta- • Treatment is recommended for 4-8 weeks. Brain abscesses in our cohort were typically diagnosed by computer topography (CT) scan, 1 4 2 in some cases followed by magnetic resonance imaging (MRI) to delineate further. We 1 4 3 collected radiology data for the definitive pre-treatment scan only, as subsequent sequential  Microbiology diagnostic work was undertaken in our ISO approved clinical diagnostic 1 5 2 laboratory. Methods were based on National Standard Methods (PHE) (16). In brief, samples 1 5 3 from brain abscesses were handled as follows: a Gram stain was undertaken and the 1 5 4 sample was inoculated into (i) cooked meat enrichment broth (extended incubation for 10 1 5 5 days in aerobic conditions), (ii) blood, chocolate and MacKonkey agar incubated in 5% CO2, 1 5 6 (iii) blood, NAT and neomycin agar (in anaerobic conditions with metronidazole discs). All were incubated at 35-37°C. Growth on any plate was followed up by identification using by 1 5 8 mass spectrometry (Maldi-TOF). Antibiotic susceptibility was determined on the automated 1 5 9 Phoenix platform (Becton Dickinson). Examination for additional specific pathogens would 1 6 0 be undertaken at the request of the clinical team or based on attributes of the patient's 1 6 1 background or presenting features (e.g. mycobacteria, nocardia, fungi, acanthamoeba). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020. on the Becton Dickinson BACTEC FX system, using a standard operating procedure based 1 6 5 on SMI B 37: 'investigation of blood cultures' (17).  Descriptive statistics of the data was collated using Microsoft Excel and SPSS software 1 7 8 packages. Univariate associations were explored using Fisher's Exact Test, one-way 1 7 9 ANOVA or Kruskal-Wallis statistical tests, depending on the modality and distribution of the 1 8 0 data. (n=36; 77%), in keeping with previous case series (8,9). The median age was 47 years 1 9 0 (range 17-91). An identifiable risk factor for brain abscesses was identified in 26 (55%; Table   1 9 1 1). 1 9 2 1 9 3

Brain abscesses were typically single lesions caused by Streptococcus intermedius
The majority of abscesses were a single lesion (n=36; 77%), commonest sites were frontal 1 9 5 (n=15; 32%) and parietal (n=8; 17%); Table 2. Microbiological diagnosis was made in 39/47 1 9 6 cases (83% ; Table 3), of which 34 were cultured from pus and five from blood cultures. Strikingly, organisms of the S. milleri group accounted for 29/39 cases in which diagnostic 1 9 8 data were available (74%), among which S. intermedius accounted for the majority (19/29; 1 9 9 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020. ; https://doi.org/10.1101/2020.01.25.20018788 doi: medRxiv preprint 7 66%). In one case, S. milleri was identified from an orbital swab that had been collected in We investigated whether the presence of S. milleri was associated with any clinical or 2 0 5 radiological characteristics and identified a significant relationship only with the size of the 2 0 6 abscess (median cross-sectional size of abscess 930mm 3 for S. milleri vs 190mm 3 for other 2 0 7 organisms; p=0.0005; Suppl Table 1). Among our 47 patients, 38 (81%) had an intervention to drain the abscess, and 15 2 1 2 underwent >1 drainage procedure (Suppl Table 2). The median time between admission for 2 1 3 the brain abscess and first procedure (where first microbiological samples were taken) was 1 2 1 4 day (range 0 -10 days). One individual had an elective biopsy for a presumed tumour. When the microbiology and histology suggested a diagnosis of a brain abscess, the patient 2 1 6 was admitted for treatment 11 days later. All patients were treated with intravenous 2 1 7 antibiotics, predominantly ceftriaxone, with alternative choices justified on the grounds of 2 1 8 clinical context and/or microbiology (Table 4). Duration of IV therapy was most commonly 6 2 1 9 weeks while oral therapy varied from 2-8 weeks (Suppl Fig 2). Ten patients died (21%). Five (50%) deaths occurred before completion of the primary 2 2 3 intravenous antimicrobial course and were directly attributable to the brain abscess (median 2 2 4 9 days after presentation; range 1-50 days), three were after the completion of treatment but 2 2 5 showed possible attribution to brain abscess (median time post-presentation 116 days; 2 2 6 range 76-146 days). One was attributed to unrelated comorbidities (113 days post-2 2 7 presentation), and one died at another centre with no further data available (146 days post-2 2 8 presentation). Of the 10 deaths, seven had significant medical comorbidities, including  were significantly associated with mortality on univariate analysis (p=0.005, p=0.04, p=0.03, 2 3 4 respectively; Table 5). Mortality was not significantly associated with any radiological 2 3 5 features or with any specific microbiological diagnosis. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020. In this UK cohort of brain abscess patients, we found a low prevalence of Staphylococcal 2 4 0 infection and a predominance of Streptococcal species, in particular S. intermedius of the S. identified a pathogen in 83% of cases, which is comparable to another recent UK case 2 4 3 series (7) and compares favourably with two other data sets in which <60% of cases had a 2 4 4 microbiological diagnosis (8,9). Improvements in sampling techniques, especially with improvements in identification rates. The dominance of S. milleri species is consistent with other published UK epidemiological 2 5 2 datasets on causative microbiology (7,8,21) and temporal trends in brain abscess  group by species (7). It is unclear how important speciation within the S milleri group is in 2 5 8 clinical practice, given the entire group tends to be penicillin sensitive. S. intermedius may be 2 5 9 dominant in brain abscesses as a result of its ecological niche in dental, sinus and ear 2 6 0 infections (28). Its particular tendency to form abscesses may relate to the presence of 2 6 1 specific virulence factors, including enzymes that digest host tissue (such as sialidase, 2 6 2 hyaluronidase, and human-specific cytolysin) (29), and factors that enhance binding to significantly larger size of abscesses we found in association with these organisms. Another striking finding from the microbiological data is the relative lack of staphylococcal 2 6 7 infections. A recent systematic review reported staphylococci as still causing approximately 2 6 8 20% of brain abscesses (6), but S.aureus was found in <10% of cases in another recent UK previous literature (6,9,31). This may be partly reflective of the difficulty in culturing 2 7 2 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020. ; https://doi.org/10.1101/2020.01.25.20018788 doi: medRxiv preprint 9 anaerobes, although the accumulation of more robust diagnostic microbiological data may 2 7 3 call into question the role of anaerobes in intracranial abscesses. Our data demonstrate that ceftriaxone with metronidazole currently remains a safe empiric 2 7 7 antimicrobial regimen in our setting (32). Narrower spectrum agents could be considered for 2 7 8 the treatment of fully sensitive streptococci when supported by laboratory data but may be 2 7 9 less easy to administer in one or two daily doses. Furthermore, culture-based methods may nausea, and prolonged therapy is associated with a risk of neuropathy. Four to six weeks of therapy is typically suggested for intravenous ceftriaxone (5), but given 2 8 7 the ongoing international drive to restrict and reduce the duration and use of broad spectrum therapy, but in practice are difficult to conduct for a rare condition. The lack of guidance 2 9 4 available on the choice, course and use of oral antibiotics (10,13) is reflected in our findings 2 9 5 of a wide range of choices for follow-on antibiotics and their duration. Despite prompt surgical drainage and prolonged courses of antibiotic therapy, the mortality 2 9 9 rate of this condition remains high, particularly in the context of frailty (in this setting, 3 0 0 associated with immunocompromise, cardiac anomalies and older age). There was no 3 0 1 increased mortality among patients in whom we did not secure a microbiological diagnosis, 3 0 2 suggesting that empiric therapy is also covering the underlying organisms present in this receiving no follow-on antibiotics; however, only one of these deaths was definitively 3 0 5 attributable to brain abscess, while the other four were associated with significant co-  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020. ; https://doi. org/10.1101/2020.01.25.20018788 doi: medRxiv preprint 1 0 Our data rely upon the accuracy of diagnostic coding: just as some non-brain abscess cases 3 1 0 were erroneously coded as G06.0, some genuine brain abscess cases may have been 3 1 1 coded with a different ICD code. This relatively low incidence rate highlights the difficulties of 3 1 2 performing interventional trials to examine conclusions further, and any such trial would need 3 1 3 to be coordinated across multiple centres. Our findings apply to a specific setting in the UK and should be extrapolated with caution.

1 6
We recognise that the tertiary nature of our hospital may also bias the case-mix, either as a 3 1 7 result of over-representing complex cases that need specialist multi-disciplinary to transfer (with high mortality) and those with simple/limited disease who are managed in 3 2 0 local hospitals without the need for referral to a specialist centre. We restricted the remit of 3 2 1 our audit to adults, and we are therefore unable to extend our conclusions to brain  From this study of the diagnosis and management of brain abscesses, we have provided prospective studies may be required to provide evidence underpinning the optimum choice, 3 3 3 route and duration of antibiotic therapy. This research did not receive any specific grant from funding agencies in the public, collection, analysis or interpretation of data, in the writing of the report, or in the decision to  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020. ; https://doi.org/10.1101/2020.01.25.20018788 doi: medRxiv preprint 1 2 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020. ; https://doi.org/10.1101/2020.01.25.20018788 doi: medRxiv preprint 1 3 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 28, 2020.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 28, 2020. ; https://doi.org/10.1101/2020.01.25.20018788 doi: medRxiv preprint 1 5 whether the remaining 17 were offered a test.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 28, 2020. ; https://doi.org/10. 1101/2020